Atai Life Sciences N.V. (NASDAQ: ATAI) is -53.76% lower on its value in year-to-date trading and has touched a low of $1.15 and a high of $5.80 in the current 52-week trading range. The question becomes, what are the chances the stock will make a comeback and enjoy potential growth. Why not look at analysts view on what the future holds for the stock. The ATAI stock was last observed hovering at around $1.18 in the last trading session, with the day’s gains setting it 0.05% off its average median price target of $11.00 for the next 12 months. It is also 94.14% off the consensus price target high of $21.00 offered by 14 analysts, but current levels are 75.88% higher than the price target low of $5.10 for the same period.
Currently trading at $1.23, the stock is -22.70% and -31.84% below its SMA20 and SMA50 respectively. However, with a daily trading volume of 0.95 million and changing 4.24% at the moment leaves the stock -60.77% off its SMA200. ATAI registered -75.74% loss for a year compared to 6-month loss of -69.10%.
Do You Know The Best Place To Find Gains In Volatile Markets?
In today's chaotic marketplace, the biggest gains will come from some currently-small companies that pass by older, larger businesses still stuck in a pre-pandemic world. The trick is figuring out which small caps will be tomorrow's winners. That's why StockWire News has put together a special Wealth Building Report, highlighting 3 small cap stocks set to soar in 2023.
Click here for full details and to join for free.
Sponsored
The stock witnessed a -31.28% gain in the last 1 month and extending the period to 3 months gives it a -60.06%, and is -16.89% down over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 9.77% over the week and 7.23% over the month.
Atai Life Sciences N.V. (ATAI) has around 81 employees, a market worth around $210.95M and $0.40M in sales. Distance from 52-week low is 6.96% and -78.79% from its 52-week high. The company has generated returns on investments over the last 12 months (-35.00%).
Atai Life Sciences N.V. (ATAI) Analyst Forecasts
Analyst recommendations provided by FactSet shows that the consensus forecast for Atai Life Sciences N.V. (ATAI) is a “Buy”. 14 analysts offering their recommendations for the stock have an average rating of 1.70, where 1 rate it as a Hold and 0 think it is a “Overweight”. 13 of the analysts rate the stock as a “Buy”. 0 analysts have rated the stock as a Sell or Underperform.
Atai Life Sciences N.V. is expected to release its quarterly report on 05/15/2023.The EPS is expected to shrink by -9.00% this year
Atai Life Sciences N.V. (ATAI) Top Institutional Holders
The shares outstanding are 156.61M, and float is at 150.49M with Short Float at 2.70%.
Atai Life Sciences N.V. (ATAI) Insider Activity
The most recent transaction is an insider purchase by Apeiron Investment Group Ltd., the company’s 10% Owner. SEC filings show that Apeiron Investment Group Ltd. bought 21,900 shares of the company’s common stock on Apr 29 at a price of $4.47 per share for a total of $97801.0. Following the purchase, the insider now owns 1.8 million shares.
Atai Life Sciences N.V. disclosed in a document filed with the SEC on Apr 28 that Apeiron Investment Group Ltd. (10% Owner) bought a total of 34,700 shares of the company’s common stock. The trade occurred on Apr 28 and was made at $4.46 per share for $0.15 million. Following the transaction, the insider now directly holds 1.78 million shares of the ATAI stock.
Still, SEC filings show that on Apr 27, Apeiron Investment Group Ltd. (10% Owner) acquired 19,803 shares at an average price of $4.64 for $91939.0. The insider now directly holds 1,742,702 shares of Atai Life Sciences N.V. (ATAI).
Atai Life Sciences N.V. (ATAI): Who are the competitors?
The company’s main competitors (and peers) include Johnson & Johnson (JNJ) that is trading -10.10% down over the past 12 months and Novan Inc. (NOVN) that is -64.31% lower over the same period. Biogen Inc. (BIIB) is 35.40% up on the 1-year trading charts.
